Slavé Petrovski
As the Vice President of AstraZeneca’s Centre for Genomics Research, I am dedicated to advancing genomics research with the aim to discover and develop some of the most advanced, novel and groundbreaking medicines for patients. My expertise spans population genetics, multi-omics, machine learning, and precision medicine, driving breakthroughs in target discovery and validation across disease areas. My work at AstraZeneca has led to the progression of numerous novel drug targets, reinforcing our commitment to improving patient outcomes through scientific innovation.
Since joining AstraZeneca in August 2017, I have played a pivotal role in designing and implementing numerous large-scale genomic studies. I am particularly passionate about enhancing AstraZeneca’s global collaboration network with academic, industry, government, and non-profit organizations to maximise our collective efforts and enhance our genomic diversity commitment. This is a vital part of the AstraZeneca Genomics Initiative, which aims to analyze two million genomes by 2026.
Today, our Centre for Genomics Research is a unified and centralised multi-omics and target-indication discovery unit within AstraZeneca. Working in close partnership across therapy areas, the CGR comprises four core functions in genomic sciences: Human Genetics (AstraZeneca’s Genomics Initiative), Dynamic Omics, Functional Genomics, and Translational Genomics. In partnership with Therapy Area colleagues, the Centre’s patient-centric focus supports the development of robust therapeutic strategies anchored in causal human biology.
We are at the forefront of integrating human genetics into drug discovery, significantly increasing the likelihood of successfully developing novel, innovative and effective medicines.
2023
2020
CURRENT ROLE
2023
2022
2021
Featured publications
Veeva ID: Z4-72188
Date of preparation: February 2025